<?xml version='1.0' encoding='utf-8'?>
<document id="29255971"><sentence text="Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects."><entity charOffset="42-53" id="DDI-PubMed.29255971.s1.e0" text="Daclatasvir" /><entity charOffset="55-66" id="DDI-PubMed.29255971.s1.e1" text="Asunaprevir" /><entity charOffset="72-82" id="DDI-PubMed.29255971.s1.e2" text="Beclabuvir" /><pair ddi="false" e1="DDI-PubMed.29255971.s1.e0" e2="DDI-PubMed.29255971.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29255971.s1.e0" e2="DDI-PubMed.29255971.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29255971.s1.e0" e2="DDI-PubMed.29255971.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29255971.s1.e1" e2="DDI-PubMed.29255971.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29255971.s1.e1" e2="DDI-PubMed.29255971.s1.e2" /></sentence><sentence text="A fixed-dose combination of daclatasvir (DCV; hepatitis C virus NS5A inhibitor), asunaprevir (ASV; non-structural protein 3 inhibitor), and beclabuvir (BCV; non-structural protein 5B inhibitor) is approved in Japan for hepatitis C virus genotype 1"><entity charOffset="28-39" id="DDI-PubMed.29255971.s2.e0" text="daclatasvir" /><entity charOffset="41-44" id="DDI-PubMed.29255971.s2.e1" text="DCV" /><entity charOffset="81-92" id="DDI-PubMed.29255971.s2.e2" text="asunaprevir" /><pair ddi="false" e1="DDI-PubMed.29255971.s2.e0" e2="DDI-PubMed.29255971.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29255971.s2.e0" e2="DDI-PubMed.29255971.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29255971.s2.e0" e2="DDI-PubMed.29255971.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29255971.s2.e1" e2="DDI-PubMed.29255971.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29255971.s2.e1" e2="DDI-PubMed.29255971.s2.e2" /></sentence><sentence text="" /><sentence text="The objective of this study was to assess the combination's drug-drug interaction potential in vivo using a validated cocktail of eight cytochrome P450 (CYP) and transporter probes" /><sentence text="" /><sentence text="We conducted an open-label single-sequence study in healthy adults (n = 20) given single-dose caffeine (CYP1A2 substrate), metoprolol (CYP2D6), flurbiprofen (CYP2C9), montelukast (CYP2C8), omeprazole (CYP2C19), midazolam (CYP3A4), digoxin (P-glycoprotein), and pravastatin (organic anion-transporting polypeptide), alone or with steady-state twice-daily DCV/ASV/BCV 30/200/75 mg (with or without additional BCV 75 mg to adjust for higher exposure in hepatitis C virus infection)"><entity charOffset="94-102" id="DDI-PubMed.29255971.s6.e0" text="caffeine" /><entity charOffset="123-133" id="DDI-PubMed.29255971.s6.e1" text="metoprolol" /><entity charOffset="135-141" id="DDI-PubMed.29255971.s6.e2" text="CYP2D6" /><entity charOffset="144-156" id="DDI-PubMed.29255971.s6.e3" text="flurbiprofen" /><entity charOffset="158-164" id="DDI-PubMed.29255971.s6.e4" text="CYP2C9" /><entity charOffset="167-178" id="DDI-PubMed.29255971.s6.e5" text="montelukast" /><entity charOffset="180-186" id="DDI-PubMed.29255971.s6.e6" text="CYP2C8" /><entity charOffset="189-199" id="DDI-PubMed.29255971.s6.e7" text="omeprazole" /><entity charOffset="201-208" id="DDI-PubMed.29255971.s6.e8" text="CYP2C19" /><entity charOffset="211-220" id="DDI-PubMed.29255971.s6.e9" text="midazolam" /><entity charOffset="231-238" id="DDI-PubMed.29255971.s6.e10" text="digoxin" /><entity charOffset="261-272" id="DDI-PubMed.29255971.s6.e11" text="pravastatin" /><entity charOffset="354-364" id="DDI-PubMed.29255971.s6.e12" text="DCV" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e0" e2="DDI-PubMed.29255971.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e0" e2="DDI-PubMed.29255971.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e0" e2="DDI-PubMed.29255971.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e0" e2="DDI-PubMed.29255971.s6.e3" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e0" e2="DDI-PubMed.29255971.s6.e4" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e0" e2="DDI-PubMed.29255971.s6.e5" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e0" e2="DDI-PubMed.29255971.s6.e6" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e0" e2="DDI-PubMed.29255971.s6.e7" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e0" e2="DDI-PubMed.29255971.s6.e8" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e0" e2="DDI-PubMed.29255971.s6.e9" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e0" e2="DDI-PubMed.29255971.s6.e10" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e0" e2="DDI-PubMed.29255971.s6.e11" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e0" e2="DDI-PubMed.29255971.s6.e12" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e1" e2="DDI-PubMed.29255971.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e1" e2="DDI-PubMed.29255971.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e1" e2="DDI-PubMed.29255971.s6.e3" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e1" e2="DDI-PubMed.29255971.s6.e4" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e1" e2="DDI-PubMed.29255971.s6.e5" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e1" e2="DDI-PubMed.29255971.s6.e6" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e1" e2="DDI-PubMed.29255971.s6.e7" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e1" e2="DDI-PubMed.29255971.s6.e8" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e1" e2="DDI-PubMed.29255971.s6.e9" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e1" e2="DDI-PubMed.29255971.s6.e10" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e1" e2="DDI-PubMed.29255971.s6.e11" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e1" e2="DDI-PubMed.29255971.s6.e12" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e2" e2="DDI-PubMed.29255971.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e2" e2="DDI-PubMed.29255971.s6.e3" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e2" e2="DDI-PubMed.29255971.s6.e4" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e2" e2="DDI-PubMed.29255971.s6.e5" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e2" e2="DDI-PubMed.29255971.s6.e6" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e2" e2="DDI-PubMed.29255971.s6.e7" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e2" e2="DDI-PubMed.29255971.s6.e8" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e2" e2="DDI-PubMed.29255971.s6.e9" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e2" e2="DDI-PubMed.29255971.s6.e10" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e2" e2="DDI-PubMed.29255971.s6.e11" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e2" e2="DDI-PubMed.29255971.s6.e12" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e3" e2="DDI-PubMed.29255971.s6.e3" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e3" e2="DDI-PubMed.29255971.s6.e4" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e3" e2="DDI-PubMed.29255971.s6.e5" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e3" e2="DDI-PubMed.29255971.s6.e6" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e3" e2="DDI-PubMed.29255971.s6.e7" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e3" e2="DDI-PubMed.29255971.s6.e8" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e3" e2="DDI-PubMed.29255971.s6.e9" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e3" e2="DDI-PubMed.29255971.s6.e10" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e3" e2="DDI-PubMed.29255971.s6.e11" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e3" e2="DDI-PubMed.29255971.s6.e12" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e4" e2="DDI-PubMed.29255971.s6.e4" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e4" e2="DDI-PubMed.29255971.s6.e5" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e4" e2="DDI-PubMed.29255971.s6.e6" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e4" e2="DDI-PubMed.29255971.s6.e7" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e4" e2="DDI-PubMed.29255971.s6.e8" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e4" e2="DDI-PubMed.29255971.s6.e9" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e4" e2="DDI-PubMed.29255971.s6.e10" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e4" e2="DDI-PubMed.29255971.s6.e11" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e4" e2="DDI-PubMed.29255971.s6.e12" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e5" e2="DDI-PubMed.29255971.s6.e5" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e5" e2="DDI-PubMed.29255971.s6.e6" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e5" e2="DDI-PubMed.29255971.s6.e7" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e5" e2="DDI-PubMed.29255971.s6.e8" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e5" e2="DDI-PubMed.29255971.s6.e9" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e5" e2="DDI-PubMed.29255971.s6.e10" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e5" e2="DDI-PubMed.29255971.s6.e11" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e5" e2="DDI-PubMed.29255971.s6.e12" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e6" e2="DDI-PubMed.29255971.s6.e6" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e6" e2="DDI-PubMed.29255971.s6.e7" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e6" e2="DDI-PubMed.29255971.s6.e8" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e6" e2="DDI-PubMed.29255971.s6.e9" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e6" e2="DDI-PubMed.29255971.s6.e10" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e6" e2="DDI-PubMed.29255971.s6.e11" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e6" e2="DDI-PubMed.29255971.s6.e12" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e7" e2="DDI-PubMed.29255971.s6.e7" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e7" e2="DDI-PubMed.29255971.s6.e8" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e7" e2="DDI-PubMed.29255971.s6.e9" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e7" e2="DDI-PubMed.29255971.s6.e10" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e7" e2="DDI-PubMed.29255971.s6.e11" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e7" e2="DDI-PubMed.29255971.s6.e12" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e8" e2="DDI-PubMed.29255971.s6.e8" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e8" e2="DDI-PubMed.29255971.s6.e9" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e8" e2="DDI-PubMed.29255971.s6.e10" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e8" e2="DDI-PubMed.29255971.s6.e11" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e8" e2="DDI-PubMed.29255971.s6.e12" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e9" e2="DDI-PubMed.29255971.s6.e9" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e9" e2="DDI-PubMed.29255971.s6.e10" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e9" e2="DDI-PubMed.29255971.s6.e11" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e9" e2="DDI-PubMed.29255971.s6.e12" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e10" e2="DDI-PubMed.29255971.s6.e10" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e10" e2="DDI-PubMed.29255971.s6.e11" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e10" e2="DDI-PubMed.29255971.s6.e12" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e11" e2="DDI-PubMed.29255971.s6.e11" /><pair ddi="false" e1="DDI-PubMed.29255971.s6.e11" e2="DDI-PubMed.29255971.s6.e12" /></sentence><sentence text="" /><sentence text="Daclatasvir/asunaprevir/beclabuvir did not affect CYP1A2, CYP2C8, or CYP2C9; the probe maximum observed concentration and area under the concentration-time curve extrapolated to infinite time geometric mean ratios and 90% confidence intervals were all within the 0"><entity charOffset="0-11" id="DDI-PubMed.29255971.s8.e0" text="Daclatasvir" /><entity charOffset="12-23" id="DDI-PubMed.29255971.s8.e1" text="asunaprevir" /><pair ddi="false" e1="DDI-PubMed.29255971.s8.e0" e2="DDI-PubMed.29255971.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29255971.s8.e0" e2="DDI-PubMed.29255971.s8.e1" /></sentence><sentence text="8-1" /><sentence text="25 bioequivalence range" /><sentence text=" Beclabuvir showed moderate dose-dependent CYP2C19 induction; omeprazole maximum observed concentration and area under the concentration-time curve from 0 to the last quantifiable concentration were lower with additional BCV [geometric mean ratio 0"><entity charOffset="1-11" id="DDI-PubMed.29255971.s11.e0" text="Beclabuvir" /><entity charOffset="62-72" id="DDI-PubMed.29255971.s11.e1" text="omeprazole" /><pair ddi="false" e1="DDI-PubMed.29255971.s11.e0" e2="DDI-PubMed.29255971.s11.e0" /><pair ddi="false" e1="DDI-PubMed.29255971.s11.e0" e2="DDI-PubMed.29255971.s11.e1" /></sentence><sentence text="36 (90% confidence interval 0" /><sentence text="23-0" /><sentence text="55) and 0" /><sentence text="34 (0" /><sentence text="25-0" /><sentence text="46), respectively] than without [0" /><sentence text="57 (0" /><sentence text="42-0" /><sentence text="78), 0" /><sentence text="48 (0" /><sentence text="39-0" /><sentence text="59)]" /><sentence text=" Weak-to-moderate CYP3A4 induction was observed, plus weak CYP2D6, P-glycoprotein, and organic anion-transporting polypeptide inhibition [maximum observed concentration and area under the concentration-time curve extrapolated to infinite time without additional BCV: midazolam 0"><entity charOffset="267-276" id="DDI-PubMed.29255971.s24.e0" text="midazolam" /></sentence><sentence text="57 (0" /><sentence text="50-0" /><sentence text="65), 0" /><sentence text="53 (0" /><sentence text="47-0" /><sentence text="60); metoprolol 1"><entity charOffset="5-15" id="DDI-PubMed.29255971.s30.e0" text="metoprolol" /></sentence><sentence text="40 (1" /><sentence text="20-1" /><sentence text="64), 1" /><sentence text="71 (1" /><sentence text="49-1" /><sentence text="97); digoxin 1" /><sentence text="23 (1" /><sentence text="12-1" /><sentence text="35), 1" /><sentence text="23 (1" /><sentence text="17-1" /><sentence text="29); pravastatin 2"><entity charOffset="5-16" id="DDI-PubMed.29255971.s42.e0" text="pravastatin" /></sentence><sentence text="01 (1" /><sentence text="63-2" /><sentence text="47), 1" /><sentence text="68 (1" /><sentence text="43-1" /><sentence text="97)]" /><sentence text="" /><sentence text="No dose adjustments with DCV/ASV/BCV are indicated for CYP1A2, CYP2C8, CYP2C9, or P-glycoprotein substrates"><entity charOffset="25-35" id="DDI-PubMed.29255971.s50.e0" text="DCV" /></sentence><sentence text=" CYP3A4, CYP2D6, and OATP substrates should be co-administered with caution" /><sentence text=" Co-administration with agents solely metabolized by CYP2C19 is not recommended" /><sentence text="" /></document>